Myriad's Presents Positive Clinical Data on HRD Test at SABCS 2013
December 14, 2013 at 08:33 AM EST
Myriad Genetics (Nasdaq: MYGN ) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer. In this research study, Myriad's HRD test provided optimal prediction of